For example, analysis of vesicles-associated nucleic acids for common B-Raf proto-oncogene (BRAF), KRAS Proto-Oncogene (KRAS), and epidermal growth factor receptor (EGFR) mutations has shown higher sensitivity compared to liquid biopsies of plasma ctDNA in association to clinical outcomes of patients with NSCLC [120]. This evidence concerns the gene BRAF and non-small cell lung carcinoma.